Login to Your Account



AVEO Drops on Possibility of Second Phase III Trial

By Mari Serebrov
Washington Editor

Wednesday, May 1, 2013
Shares of AVEO Oncology Inc. plummeted to historic lows Tuesday with the realization that the company may have to conduct a second Phase III trial before the FDA considers approving tivozanib to treat advanced renal cell carcinoma (RCC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription